Supreme Court rules for Teva over MS drug patent

WASHINGTON (Reuters) - The U.S. Supreme Court on Tuesday ruled that Teva Pharmaceutical Industries Ltd can still benefit from patent protection for top-selling multiple sclerosis drug Copaxone, dealing a blow to generic drugmakers looking to market a cheaper rival product.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news